Brief report: The uricase mutation in humans increases our risk for cancer growth.
Level 5 - mechanism / opinion, no new human data
Animal model experiment without human participants
PubMed 34526149 · doi:10.1186/s40170-021-00268-3
What was done
Researchers evaluated whether uricase inactivation affects breast cancer progression in mice. Uricase was inactivated either genetically via knockout or pharmacologically with oxonic acid; these models were compared to transgenic mice expressing uricase. Animals were injected with breast cancer cells and monitored for tumor growth and metastases over a 4-week period.
What was found
Knockout or chemical inhibition of uricase resulted in increased tumor growth and metastasis, whereas transgenic uricase expression was associated with reduced tumor growth. The abstract reports qualitative findings only and provides no quantitative data, effect sizes, or p-values.
Why it matters
The study links an evolutionary mutation—the Miocene loss of uricase that facilitated fat accumulation—to modern cancer risk, providing a mechanistic rationale for how uric acid and fructose metabolism may accelerate tumor progression.
Limits
Findings rely entirely on preclinical mouse models using a single cancer cell line over a short 4-week window, limiting direct clinical translation to humans. The abstract omits sample sizes, numerical measurements of tumor volumes, metastatic burdens, and statistical parameters.
Cited by
- supports In mice lacking functional uricase or with uricase inhibited, cancers metastasize much faster in the presence of high uric acid.